![Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca](https://www.canada.ca/content/dam/phac-aspc/images/services/publications/healthy-living/update-use-of-13-valent-pneumococcal-conjugate-vaccine-pneu-c-13-in-addition-to-23-valent-pneumococcal-polysaccharide-vaccine-pneu-p-23-immunocompetent-adults-65-years-and-older-interim-recommendation/figure-3-eng.gif)
Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca
![A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X21010975-gr3.jpg)
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect
![Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca](https://www.canada.ca/content/dam/phac-aspc/images/services/publications/healthy-living/update-use-of-13-valent-pneumococcal-conjugate-vaccine-pneu-c-13-in-addition-to-23-valent-pneumococcal-polysaccharide-vaccine-pneu-p-23-immunocompetent-adults-65-years-and-older-interim-recommendation/figure-4-eng.gif)
Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation - Canada.ca
![Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study ( PNEU-PED-EU-2) - ScienceDirect Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study ( PNEU-PED-EU-2) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X23001767-gr3.jpg)
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study ( PNEU-PED-EU-2) - ScienceDirect
![A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X21010975-gr5.jpg)
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE) - ScienceDirect
![Use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines: NACI public health level recommendations. - Canada.ca Use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines: NACI public health level recommendations. - Canada.ca](https://www.canada.ca/content/dam/phac-aspc/images/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/figure03-eng.jpg)
Use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines: NACI public health level recommendations. - Canada.ca
![Frontiers | Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco Frontiers | Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco](https://www.frontiersin.org/files/Articles/903376/fpubh-10-903376-HTML/image_m/fpubh-10-903376-t001.jpg)
Frontiers | Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco
![For BMW R1250GS R1200GS LC ADV GSA R 1250 GS Adventure Motorcycle Accessories CNC Wheel Tire Valve Caps Air Stem Cover Plugs - AliExpress For BMW R1250GS R1200GS LC ADV GSA R 1250 GS Adventure Motorcycle Accessories CNC Wheel Tire Valve Caps Air Stem Cover Plugs - AliExpress](https://ae01.alicdn.com/kf/S42ee764da6bf4bb38044d7a4e12debc2A/For-BMW-R1250GS-R1200GS-LC-ADV-GSA-R-1250-GS-Adventure-Motorcycle-Accessories-CNC-Wheel-Tire.jpg)